Lamprene

Overview

clofazimine

antimycobacterial

• CYP2C8 inhibitor, weak
• CYP2D6 inhibitor, weak
• CYP3A4 inhibitor, moderate
• alters GI flora
• impairs immunomodulatory bacterial infective agent
• prolongs QT interval (known)

Contraindicated

• cisapride
Lamprene (clofazimine)

+

cisapride

1 interaction

Contraindicated

clofazimine + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• domperidone
Lamprene (clofazimine)

+

domperidone

1 interaction

Contraindicated

clofazimine + domperidone

contraindicated: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• dronedarone
Lamprene (clofazimine)

+

dronedarone

1 interaction

Contraindicated

clofazimine + dronedarone

contraindicated: combo may incr. dronedarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• flibanserin
Lamprene (clofazimine)

+

flibanserin

1 interaction

Contraindicated

clofazimine + flibanserin

contraindicated w/in 14 days prior to, during, and x2 days after flibanserin tx: combo may incr. flibanserin levels, risk of CNS depression, psychomotor impairment, severe hypotension (incl. syncope), other adverse effects (hepatic metab. inhibited)

• levoketoconazole
Lamprene (clofazimine)

+

levoketoconazole

1 interaction

Contraindicated

clofazimine + levoketoconazole

contraindicated: combo may incr. levoketoconazole levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lomitapide
Lamprene (clofazimine)

+

lomitapide

1 interaction

Contraindicated

clofazimine + lomitapide

contraindicated: combo may incr. lomitapide levels, risk of adverse effects (hepatic metab. inhibited)

• pimozide
Lamprene (clofazimine)

+

pimozide

1 interaction

Contraindicated

clofazimine + pimozide

contraindicated: combo may incr. pimozide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• thioridazine
Lamprene (clofazimine)

+

thioridazine

1 interaction

Contraindicated

clofazimine + thioridazine

contraindicated: combo may incr. thioridazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. possibly inhibited, additive effects)

Avoid/Use Alternative

• adagrasib
Lamprene (clofazimine)

+

adagrasib

1 interaction

Avoid/Use Alternative

clofazimine + adagrasib

use alternative or monitor ECG, electrolytes: combo may incr. adagrasib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• alfentanil
Lamprene (clofazimine)

+

alfentanil

1 interaction

Avoid/Use Alternative

clofazimine + alfentanil

use alternative or monitor resp. rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and resp. depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metab. inhibited)

• alprazolam
Lamprene (clofazimine)

+

alprazolam

1 interaction

Avoid/Use Alternative

clofazimine + alprazolam

use alternative or monitor resp. rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• amiodarone
Lamprene (clofazimine)

+

amiodarone

1 interaction

Avoid/Use Alternative

clofazimine + amiodarone

use alternative or monitor ECG: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• anagrelide
Lamprene (clofazimine)

+

anagrelide

1 interaction

Avoid/Use Alternative

clofazimine + anagrelide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apomorphine
Lamprene (clofazimine)

+

apomorphine

1 interaction

Avoid/Use Alternative

clofazimine + apomorphine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aprepitant
Lamprene (clofazimine)

+

aprepitant

1 interaction

Avoid/Use Alternative

clofazimine + aprepitant

avoid combo w/ oral aprepitant; IV aprepitant use OK: combo may incr. aprepitant levels, risk of adverse effects (hepatic metab. inhibited)

• arsenic trioxide
Lamprene (clofazimine)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

clofazimine + arsenic trioxide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Lamprene (clofazimine)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

clofazimine + artemether/ lumefantrine

use alternative or monitor ECG: combo may incr. artemether/lumefantrine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• asenapine
Lamprene (clofazimine)

+

asenapine

1 interaction

Avoid/Use Alternative

clofazimine + asenapine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• avapritinib
Lamprene (clofazimine)

+

avapritinib

1 interaction

Avoid/Use Alternative

clofazimine + avapritinib

GIST: use alternative or monitor bleeding s/sx; decr. avapritinib start dose to 100 mg qd; ADVANCED SYSTEMIC MASTOCYTOSIS: use alternative or monitor bleeding s/sx; decr. avapritinib start dose to 50 mg qd; INDOLENT SYSTEMIC MASTOCYTOSIS: avoid combo: combo may incr. avapritinib levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• azithromycin
Lamprene (clofazimine)

+

azithromycin

1 interaction

Avoid/Use Alternative

clofazimine + azithromycin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• BCG live intravesical
Lamprene (clofazimine)

+

BCG live intravesical

1 interaction

Avoid/Use Alternative

clofazimine + BCG live intravesical

avoid combo: combo may decr. BCG live intravesical efficacy (antibacterial effect may interfere w/ BCG activity)

• bedaquiline
Lamprene (clofazimine)

+

bedaquiline

1 interaction

Avoid/Use Alternative

clofazimine + bedaquiline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bosentan
Lamprene (clofazimine)

+

bosentan

1 interaction

Avoid/Use Alternative

clofazimine + bosentan

avoid combo if also combined w/ CYP2C9 inhibitor; otherwise caution advised: combo may incr. bosentan levels, risk of adverse effects (hepatic metab. inhibited)

• bosutinib
Lamprene (clofazimine)

+

bosutinib

1 interaction

Avoid/Use Alternative

clofazimine + bosutinib

avoid combo: combo may incr. bosutinib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• brigatinib
Lamprene (clofazimine)

+

brigatinib

1 interaction

Avoid/Use Alternative

clofazimine + brigatinib

use alternative or monitor BP, HR; decr. brigatinib dose by approx. 40% as follows: if taking 180 mg, decr. to 120 mg, if taking 120 mg, decr. to 90 mg; if taking 90 mg, decr. to 60 mg: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects (hepatic metab. inhibited)

• buspirone
Lamprene (clofazimine)

+

buspirone

1 interaction

Avoid/Use Alternative

clofazimine + buspirone

consider alternative or restart buspirone dose at 2.5 mg bid: combo may incr. buspirone levels, risk of adverse effects (hepatic metab. inhibited)

• cabozantinib
Lamprene (clofazimine)

+

cabozantinib

1 interaction

Avoid/Use Alternative

clofazimine + cabozantinib

use alternative or monitor ECG, BP, bleeding s/sx: combo may incr. cabozantinib levels, risk of QT prolongation, cardiac arrhythmias, HTN, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• cholera vaccine, live
Lamprene (clofazimine)

+

cholera vaccine, live

1 interaction

Avoid/Use Alternative

clofazimine + cholera vaccine, live

avoid vaccine until at least 14 days after clofazimine course complete: combo may result in inadequate vaccine response (antibiotic effect may inactivate vaccine)

• citalopram
Lamprene (clofazimine)

+

citalopram

1 interaction

Avoid/Use Alternative

clofazimine + citalopram

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clarithromycin
Lamprene (clofazimine)

+

clarithromycin

1 interaction

Avoid/Use Alternative

clofazimine + clarithromycin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cobimetinib
Lamprene (clofazimine)

+

cobimetinib

1 interaction

Avoid/Use Alternative

clofazimine + cobimetinib

avoid combo or decr. cobimetinib dose to 20 mg/day and D/C clofazimine w/in 14 days: combo may incr. cobimetinib levels, risk of adverse effects (hepatic metab. inhibited)

• codeine
Lamprene (clofazimine)

+

codeine

1 interaction

Avoid/Use Alternative

clofazimine + codeine

use alternative or monitor resp. rate, withdrawal sx; consider decr. codeine dose: combo may incr. codeine, alter active metabolite morphine levels, incr. risk of CNS and resp. depression, psychomotor impairment, other adverse effects or decr. efficacy (hepatic metab. inhibited, may alter production of active metabolite morphine)

• colchicine
Lamprene (clofazimine)

+

colchicine

1 interaction

Avoid/Use Alternative

clofazimine + colchicine

CV RISK REDUCTION: avoid combo in pts w/ renal or hepatic impairment; otherwise, monitor CK, myopathy s/sx; GOUT or FMF: use alternative or decr. colchicine dose based on indication during and x14 days after clofazimine use as follows: GOUT PROPHYLAXIS: give colchicine 0.3-0.6 mg/day divided qd-bid; ACUTE GOUT TX: avoid combo if already receiving colchicine for gout prophylaxis; otherwise, give colchicine 1.2 mg x1 only; FMF: decr. max colchicine dose to 1.2 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metab. inhibited)

• conivaptan
Lamprene (clofazimine)

+

conivaptan

1 interaction

Avoid/Use Alternative

clofazimine + conivaptan

consider alternative: combo may incr. conivaptan levels, risk of overly rapid serum sodium correction, neurologic sequelae, other adverse effects (hepatic metab. inhibited)

• crizotinib
Lamprene (clofazimine)

+

crizotinib

1 interaction

Avoid/Use Alternative

clofazimine + crizotinib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. crizotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• defactinib
Lamprene (clofazimine)

+

defactinib

1 interaction

Avoid/Use Alternative

clofazimine + defactinib

avoid combo: combo may incr. defactinib levels, risk of adverse effects (hepatic metab. inhibited)

• degarelix
Lamprene (clofazimine)

+

degarelix

1 interaction

Avoid/Use Alternative

clofazimine + degarelix

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Lamprene (clofazimine)

+

desflurane

1 interaction

Avoid/Use Alternative

clofazimine + desflurane

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desipramine
Lamprene (clofazimine)

+

desipramine

1 interaction

Avoid/Use Alternative

clofazimine + desipramine

use alternative or monitor desipramine levels, ECG: combo may incr. desipramine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. possibly inhibited, additive effects)

• dexmedetomidine
Lamprene (clofazimine)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

clofazimine + dexmedetomidine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Lamprene (clofazimine)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

clofazimine + dexmedetomidine injection

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dihydrocodeine
Lamprene (clofazimine)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

clofazimine + dihydrocodeine

use alternative or monitor resp. rate, withdrawal sx; consider decr. dihydrocodeine dose: combo may incr. dihydrocodeine levels, alter metabolite dihydromorphine levels, incr. risk of CNS and resp. depression, psychomotor impairment, other adverse effects or decr. efficacy (hepatic metab. inhibited, may alter production of active metabolite dihydromorphine)

• dihydroergotamine
Lamprene (clofazimine)

+

dihydroergotamine

1 interaction

Avoid/Use Alternative

clofazimine + dihydroergotamine

use alternative: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• disopyramide
Lamprene (clofazimine)

+

disopyramide

1 interaction

Avoid/Use Alternative

clofazimine + disopyramide

use alternative or monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• dofetilide
Lamprene (clofazimine)

+

dofetilide

1 interaction

Avoid/Use Alternative

clofazimine + dofetilide

use alternative or monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• doxorubicin
Lamprene (clofazimine)

+

doxorubicin

1 interaction

Avoid/Use Alternative

clofazimine + doxorubicin

avoid combo: combo may incr. doxorubicin levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metab. inhibited)

• droperidol
Lamprene (clofazimine)

+

droperidol

1 interaction

Avoid/Use Alternative

clofazimine + droperidol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• efavirenz
Lamprene (clofazimine)

+

efavirenz

1 interaction

Avoid/Use Alternative

clofazimine + efavirenz

consider alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• elacestrant
Lamprene (clofazimine)

+

elacestrant

1 interaction

Avoid/Use Alternative

clofazimine + elacestrant

avoid combo: combo may incr. elacestrant levels, risk of adverse effects (hepatic metab. inhibited)

• eliglustat
Lamprene (clofazimine)

+

eliglustat

1 interaction

Avoid/Use Alternative

clofazimine + eliglustat

CYP2D6 EM: monitor ECG; decr. eliglustat dose to 84 mg qd; CYP2D6 IM or PM: avoid combo: combo may incr. eliglustat levels, risk of PR or QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• encorafenib
Lamprene (clofazimine)

+

encorafenib

1 interaction

Avoid/Use Alternative

clofazimine + encorafenib

use alternative or monitor ECG, electrolytes; decr. encorafenib 450 mg dose to 225 mg, decr. 300 mg dose to 150 mg, decr. 225 mg dose to 75 mg, and decr. 150 mg dose to 75 mg: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ensartinib
Lamprene (clofazimine)

+

ensartinib

1 interaction

Avoid/Use Alternative

clofazimine + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (hepatic metab. possibly inhibited)

• entrectinib
Lamprene (clofazimine)

+

entrectinib

1 interaction

Avoid/Use Alternative

clofazimine + entrectinib

avoid combo: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• ephedra
Lamprene (clofazimine)

+

ephedra

1 interaction

Avoid/Use Alternative

clofazimine + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ergotamine
Lamprene (clofazimine)

+

ergotamine

1 interaction

Avoid/Use Alternative

clofazimine + ergotamine

use alternative: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• eribulin
Lamprene (clofazimine)

+

eribulin

1 interaction

Avoid/Use Alternative

clofazimine + eribulin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Lamprene (clofazimine)

+

erythromycin

1 interaction

Avoid/Use Alternative

clofazimine + erythromycin

use alternative or monitor ECG: combo may incr. erythromycin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• etrasimod
Lamprene (clofazimine)

+

etrasimod

1 interaction

Avoid/Use Alternative

clofazimine + etrasimod

if CYP2C9 poor metabolizer or if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG: combo may incr. etrasimod levels, risk of AV block, bradycardia, QT prolongation, cardiac arrhythmias, serious infection, other adverse effects (hepatic metab. inhibited, additive effects)

• fentanyl
Lamprene (clofazimine)

+

fentanyl

1 interaction

Avoid/Use Alternative

clofazimine + fentanyl

use alternative or monitor resp. rate, consider decr. fentanyl dose: combo may incr. fentanyl levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• fexinidazole
Lamprene (clofazimine)

+

fexinidazole

1 interaction

Avoid/Use Alternative

clofazimine + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after clofazimine D/C; use alternative or monitor ECG during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. fexinidazole active metabolite levels, efficacy (additive effects; hepatic metab. inhibited, decr. conversion to active metabolites)

• flecainide
Lamprene (clofazimine)

+

flecainide

1 interaction

Avoid/Use Alternative

clofazimine + flecainide

use alternative or monitor flecainide levels, ECG: combo may incr. flecainide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. possibly inhibited, additive effects)

• fluoxetine
Lamprene (clofazimine)

+

fluoxetine

1 interaction

Avoid/Use Alternative

clofazimine + fluoxetine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fosaprepitant
Lamprene (clofazimine)

+

fosaprepitant

1 interaction

Avoid/Use Alternative

clofazimine + fosaprepitant

avoid combo: combo may incr. aprepitant levels, risk of adverse effects (hepatic metab. inhibited)

• foscarnet
Lamprene (clofazimine)

+

foscarnet

1 interaction

Avoid/Use Alternative

clofazimine + foscarnet

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gepotidacin
Lamprene (clofazimine)

+

gepotidacin

1 interaction

Avoid/Use Alternative

clofazimine + gepotidacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• givinostat
Lamprene (clofazimine)

+

givinostat

1 interaction

Avoid/Use Alternative

clofazimine + givinostat

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• glasdegib
Lamprene (clofazimine)

+

glasdegib

1 interaction

Avoid/Use Alternative

clofazimine + glasdegib

use alternative or monitor ECG, CBC: combo may incr. glasdegib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• goserelin
Lamprene (clofazimine)

+

goserelin

1 interaction

Avoid/Use Alternative

clofazimine + goserelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• grapefruit
Lamprene (clofazimine)

+

grapefruit

1 interaction

Avoid/Use Alternative

clofazimine + grapefruit

use alternative or monitor ECG w/ large amounts of grapefruit (>1L juice): combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• histrelin
Lamprene (clofazimine)

+

histrelin

1 interaction

Avoid/Use Alternative

clofazimine + histrelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• hydrocodone
Lamprene (clofazimine)

+

hydrocodone

1 interaction

Avoid/Use Alternative

clofazimine + hydrocodone

use alternative or monitor resp. rate, ECG, electrolytes; consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• hydroxychloroquine
Lamprene (clofazimine)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

clofazimine + hydroxychloroquine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibutilide
Lamprene (clofazimine)

+

ibutilide

1 interaction

Avoid/Use Alternative

clofazimine + ibutilide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• iloperidone
Lamprene (clofazimine)

+

iloperidone

1 interaction

Avoid/Use Alternative

clofazimine + iloperidone

use alternative or monitor ECG: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• inotuzumab ozogamicin
Lamprene (clofazimine)

+

inotuzumab ozogamicin

1 interaction

Avoid/Use Alternative

clofazimine + inotuzumab ozogamicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isoflurane
Lamprene (clofazimine)

+

isoflurane

1 interaction

Avoid/Use Alternative

clofazimine + isoflurane

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ivabradine
Lamprene (clofazimine)

+

ivabradine

1 interaction

Avoid/Use Alternative

clofazimine + ivabradine

avoid combo: combo may incr. ivabradine levels, risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ivacaftor
Lamprene (clofazimine)

+

ivacaftor

1 interaction

Avoid/Use Alternative

clofazimine + ivacaftor

pts <6 mo: avoid combo; pts >6 mo decr. ivacaftor dose as follows: 6 mo-5 yo and 5-6.9 kg: give 25 mg qd; 6 mo-5 yo and 7-13.9 kg: give 50 mg qd; 6 mo-5 yo and >14 kg: give 75 mg qd; 6 yo and older: give 150 mg qd: combo may incr. ivacaftor levels, risk of adverse effects (hepatic metab. inhibited)

• ivosidenib
Lamprene (clofazimine)

+

ivosidenib

1 interaction

Avoid/Use Alternative

clofazimine + ivosidenib

use alternative or monitor ECG, electrolytes: combo may incr. ivosidenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ixabepilone
Lamprene (clofazimine)

+

ixabepilone

1 interaction

Avoid/Use Alternative

clofazimine + ixabepilone

consider alternatives or monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other toxicity (hepatic metab. inhibited)

• lefamulin
Lamprene (clofazimine)

+

lefamulin

1 interaction

Avoid/Use Alternative

clofazimine + lefamulin

use alternative or monitor ECG: combo w/ oral lefamulin may incr. lefamulin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; combo w/ IV lefamulin may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. inhibited, additive effects)

• lemborexant
Lamprene (clofazimine)

+

lemborexant

1 interaction

Avoid/Use Alternative

clofazimine + lemborexant

avoid combo: combo may incr. lemborexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• leuprolide
Lamprene (clofazimine)

+

leuprolide

1 interaction

Avoid/Use Alternative

clofazimine + leuprolide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levofloxacin
Lamprene (clofazimine)

+

levofloxacin

1 interaction

Avoid/Use Alternative

clofazimine + levofloxacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lonafarnib
Lamprene (clofazimine)

+

lonafarnib

1 interaction

Avoid/Use Alternative

clofazimine + lonafarnib

consider alternative or monitor HR, ECG, electrolytes, especially during first week when adding lonafarnib to existing clofazimine tx: combo may incr. lonafarnib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• loperamide
Lamprene (clofazimine)

+

loperamide

1 interaction

Avoid/Use Alternative

clofazimine + loperamide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lopinavir/ritonavir
Lamprene (clofazimine)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

clofazimine + lopinavir/ ritonavir

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lovastatin
Lamprene (clofazimine)

+

lovastatin

1 interaction

Avoid/Use Alternative

clofazimine + lovastatin

use alternative or monitor CK, myopathy sx; adjust lovastatin max dose to 20 mg/day: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• lurbinectedin
Lamprene (clofazimine)

+

lurbinectedin

1 interaction

Avoid/Use Alternative

clofazimine + lurbinectedin

use alternative or monitor CBC; decr. lurbinectedin dose 50%: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• macimorelin
Lamprene (clofazimine)

+

macimorelin

1 interaction

Avoid/Use Alternative

clofazimine + macimorelin

avoid combo, allowing sufficient washout time before diagnostic test: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• macitentan
Lamprene (clofazimine)

+

macitentan

1 interaction

Avoid/Use Alternative

clofazimine + macitentan

if also combined w/ strong-mod CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. macitentan levels, risk of adverse effects (hepatic metab. inhibited)

• meperidine
Lamprene (clofazimine)

+

meperidine

1 interaction

Avoid/Use Alternative

clofazimine + meperidine

use alternative or monitor resp. rate, ECG; consider decr. meperidine dose: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• methadone
Lamprene (clofazimine)

+

methadone

1 interaction

Avoid/Use Alternative

clofazimine + methadone

use alternative or monitor resp. rate, ECG, consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• methylergonovine
Lamprene (clofazimine)

+

methylergonovine

1 interaction

Avoid/Use Alternative

clofazimine + methylergonovine

avoid combo: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• midazolam
Lamprene (clofazimine)

+

midazolam

1 interaction

Avoid/Use Alternative

clofazimine + midazolam

avoid combo if midazolam nasal use; otherwise, monitor resp. rate, consider decr. midazolam dose: combo may incr. midazolam and active metabolite levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• mifepristone
Lamprene (clofazimine)

+

mifepristone

1 interaction

Avoid/Use Alternative

clofazimine + mifepristone

use alternative or monitor ECG if daily mifepristone use: combo may incr. mifepristone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• mobocertinib
Lamprene (clofazimine)

+

mobocertinib

1 interaction

Avoid/Use Alternative

clofazimine + mobocertinib

use alternative or monitor ECG, electrolytes; decr. mobocertinib dose as follows: if taking 160 mg, decr. dose to 80 mg; if taking 120 mg, decr. dose to 40 mg, if taking 80 mg, decr. dose to 40 mg: combo may incr. mobocertinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• moxifloxacin
Lamprene (clofazimine)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

clofazimine + moxifloxacin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• naloxegol
Lamprene (clofazimine)

+

naloxegol

1 interaction

Avoid/Use Alternative

clofazimine + naloxegol

use alternative or decr. naloxegol dose to 12.5 mg/day: combo may incr. naloxegol levels, risk of adverse effects (hepatic metab. inhibited)

• neratinib
Lamprene (clofazimine)

+

neratinib

1 interaction

Avoid/Use Alternative

clofazimine + neratinib

avoid combo if also combined w/ P-gp inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (hepatic metab. inhibited)

• nilotinib
Lamprene (clofazimine)

+

nilotinib

1 interaction

Avoid/Use Alternative

clofazimine + nilotinib

avoid combo: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• nirogacestat
Lamprene (clofazimine)

+

nirogacestat

1 interaction

Avoid/Use Alternative

clofazimine + nirogacestat

avoid combo: combo may incr. nirogacestat levels, risk of hypophosphatemia, other adverse effects (hepatic metab. inhibited)

• nisoldipine
Lamprene (clofazimine)

+

nisoldipine

1 interaction

Avoid/Use Alternative

clofazimine + nisoldipine

consider alternative or monitor BP: combo may incr. nisoldipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• olaparib
Lamprene (clofazimine)

+

olaparib

1 interaction

Avoid/Use Alternative

clofazimine + olaparib

use alternative or decr. olaparib dose to 150 mg bid; monitor CBC: combo may incr. olaparib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• oliceridine
Lamprene (clofazimine)

+

oliceridine

1 interaction

Avoid/Use Alternative

clofazimine + oliceridine

use alternative or monitor resp. rate, ECG; consider decr. oliceridine frequency: combo may incr. oliceridine levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• omaveloxolone
Lamprene (clofazimine)

+

omaveloxolone

1 interaction

Avoid/Use Alternative

clofazimine + omaveloxolone

use alternative or decr. omaveloxolone dose to 100 mg/day: combo may incr. omaveloxolone levels, risk of adverse effects (hepatic metab. inhibited)

• osimertinib
Lamprene (clofazimine)

+

osimertinib

1 interaction

Avoid/Use Alternative

clofazimine + osimertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxaliplatin
Lamprene (clofazimine)

+

oxaliplatin

1 interaction

Avoid/Use Alternative

clofazimine + oxaliplatin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxycodone
Lamprene (clofazimine)

+

oxycodone

1 interaction

Avoid/Use Alternative

clofazimine + oxycodone

use alternative or monitor resp. rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• ozanimod
Lamprene (clofazimine)

+

ozanimod

1 interaction

Avoid/Use Alternative

clofazimine + ozanimod

consider alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pacritinib
Lamprene (clofazimine)

+

pacritinib

1 interaction

Avoid/Use Alternative

clofazimine + pacritinib

avoid combo: combo may incr. pacritinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• paliperidone
Lamprene (clofazimine)

+

paliperidone

1 interaction

Avoid/Use Alternative

clofazimine + paliperidone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• palovarotene
Lamprene (clofazimine)

+

palovarotene

1 interaction

Avoid/Use Alternative

clofazimine + palovarotene

use alternative or decr. palovarotene dose as follows: wt 10-19.9 kg maint. dose 1 mg daily, flare dose 5 mg daily wk 1-4, then 2.5 mg daily wk 5-12; wt 20-39.9 kg maint. dose 1.5 mg daily, flare dose 6 mg daily wk 1-4, then 3 mg daily wk 5-12; wt 40-59.9 kg maint. dose 2 mg daily, flare dose 7.5 mg daily wk 1-4, then 4 mg daily wk 5-12; wt 60 kg and greater or 14 yo and older maint. dose 2.5 mg daily, flare dose 10 mg daily wk 1-4, then 5 mg daily wk 5-12: combo may incr. palovarotene levels, risk of adverse effects (hepatic metab. inhibited)

• panobinostat
Lamprene (clofazimine)

+

panobinostat

1 interaction

Avoid/Use Alternative

clofazimine + panobinostat

use alternative or monitor ECG, CBC: combo may incr. panobinostat levels, risk of QT prolongation, cardiac arrhythmias, serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• pazopanib
Lamprene (clofazimine)

+

pazopanib

1 interaction

Avoid/Use Alternative

clofazimine + pazopanib

avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• pemigatinib
Lamprene (clofazimine)

+

pemigatinib

1 interaction

Avoid/Use Alternative

clofazimine + pemigatinib

use alternative or monitor phosphate and decr. pemigatinib dose as follows: if on pemigatinib 13.5 mg qd, decr. to 9 mg qd; if on pemigatinib 9 mg qd, decr. to 4.5 mg qd: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• pentamidine
Lamprene (clofazimine)

+

pentamidine

1 interaction

Avoid/Use Alternative

clofazimine + pentamidine

use alternative or monitor ECG; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pexidartinib
Lamprene (clofazimine)

+

pexidartinib

1 interaction

Avoid/Use Alternative

clofazimine + pexidartinib

use alternative or monitor LFTs, decr. pexidartinib dose as follows: if on pexidartinib 500 mg/day or 375 mg/day, decr. to 125 mg bid; if on pexidartinib 250 mg/day, decr. to 125 mg qd: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects (hepatic metab. inhibited)

• phenobarbital
Lamprene (clofazimine)

+

phenobarbital

1 interaction

Avoid/Use Alternative

clofazimine + phenobarbital

avoid combo if neonatal seizure use; otherwise, monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pimavanserin
Lamprene (clofazimine)

+

pimavanserin

1 interaction

Avoid/Use Alternative

clofazimine + pimavanserin

avoid combo: combo may incr. pimavanserin levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• pitolisant
Lamprene (clofazimine)

+

pitolisant

1 interaction

Avoid/Use Alternative

clofazimine + pitolisant

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ponesimod
Lamprene (clofazimine)

+

ponesimod

1 interaction

Avoid/Use Alternative

clofazimine + ponesimod

use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• pralsetinib
Lamprene (clofazimine)

+

pralsetinib

1 interaction

Avoid/Use Alternative

clofazimine + pralsetinib

use alternative or monitor ECG, consider monitoring electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• procainamide
Lamprene (clofazimine)

+

procainamide

1 interaction

Avoid/Use Alternative

clofazimine + procainamide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propafenone
Lamprene (clofazimine)

+

propafenone

1 interaction

Avoid/Use Alternative

clofazimine + propafenone

avoid combo: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metab. inhibited, additive effects)

• quetiapine
Lamprene (clofazimine)

+

quetiapine

1 interaction

Avoid/Use Alternative

clofazimine + quetiapine

use alternative or monitor ECG; consider decr. quetiapine dose: combo may incr. quetiapine levels, risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, anticholinergic adverse effects, other adverse effects (hepatic metab. inhibited, additive effects)

• quinidine (antiarrhythmic)
Lamprene (clofazimine)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

clofazimine + quinidine (antiarrhythmic)

use alternative or monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• quinine
Lamprene (clofazimine)

+

quinine

1 interaction

Avoid/Use Alternative

clofazimine + quinine

use alternative or monitor ECG: combo may incr. quinine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• quizartinib
Lamprene (clofazimine)

+

quizartinib

1 interaction

Avoid/Use Alternative

clofazimine + quizartinib

use alternative or monitor ECG, electrolytes: combo may incr. quizartinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• repotrectinib
Lamprene (clofazimine)

+

repotrectinib

1 interaction

Avoid/Use Alternative

clofazimine + repotrectinib

avoid combo; D/C clofazimine 3-5 half-lives prior to repotrectinib tx: combo may incr. repotrectinib levels, risk of adverse effects (hepatic metab. inhibited)

• revumenib
Lamprene (clofazimine)

+

revumenib

1 interaction

Avoid/Use Alternative

clofazimine + revumenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Lamprene (clofazimine)

+

ribociclib

1 interaction

Avoid/Use Alternative

clofazimine + ribociclib

use alternative or monitor ECG, electrolytes, CBC: combo may incr. ribociclib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• rilpivirine
Lamprene (clofazimine)

+

rilpivirine

1 interaction

Avoid/Use Alternative

clofazimine + rilpivirine

consider alternative or monitor ECG; risk may be lower w/ IM rilpivirine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rivaroxaban
Lamprene (clofazimine)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

clofazimine + rivaroxaban

use alternative if CrCl <80 and combined w/ P-gp inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• rucaparib
Lamprene (clofazimine)

+

rucaparib

1 interaction

Avoid/Use Alternative

clofazimine + rucaparib

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• selpercatinib
Lamprene (clofazimine)

+

selpercatinib

1 interaction

Avoid/Use Alternative

clofazimine + selpercatinib

use alternative or monitor ECG, electrolytes; decr. selpercatinib dose as follows: if on selpercatinib 40 mg tid, decr. to 40 mg qd; if on selpercatinib 80 mg bid, decr. to 40 mg bid; if on selpercatinib 120 mg bid, decr. to 80 mg bid; if on selpercatinib 160 mg bid, decr. to 120 mg bid: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• selumetinib
Lamprene (clofazimine)

+

selumetinib

1 interaction

Avoid/Use Alternative

clofazimine + selumetinib

use alternative or monitor LVEF, CK, myopathy sx; decr. selumetinib dose as follows: if on selumetinib 25 mg/m^2 bid, decr. to 20 mg/m^2 bid; if on selumetinib 20 mg/m^2 bid, decr. to 15 mg/m^2 bid; see selumetinib pkg insert for specific dose adjustments: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• sertraline
Lamprene (clofazimine)

+

sertraline

1 interaction

Avoid/Use Alternative

clofazimine + sertraline

use alternative or monitor ECG: combo may incr. sertraline levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• sevoflurane
Lamprene (clofazimine)

+

sevoflurane

1 interaction

Avoid/Use Alternative

clofazimine + sevoflurane

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• simvastatin
Lamprene (clofazimine)

+

simvastatin

1 interaction

Avoid/Use Alternative

clofazimine + simvastatin

use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 10 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• siponimod
Lamprene (clofazimine)

+

siponimod

1 interaction

Avoid/Use Alternative

clofazimine + siponimod

if also combined w/ moderate or strong CYP2C9 inhibitor, avoid combo; otherwise, consider alternative or monitor HR, ECG: combo may incr. siponimod levels, risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• solifenacin
Lamprene (clofazimine)

+

solifenacin

1 interaction

Avoid/Use Alternative

clofazimine + solifenacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sonidegib
Lamprene (clofazimine)

+

sonidegib

1 interaction

Avoid/Use Alternative

clofazimine + sonidegib

avoid combo or monitor closely: combo may incr. sonidegib levels, risk of adverse effects (hepatic metab. inhibited)

• sorafenib
Lamprene (clofazimine)

+

sorafenib

1 interaction

Avoid/Use Alternative

clofazimine + sorafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sotalol
Lamprene (clofazimine)

+

sotalol

1 interaction

Avoid/Use Alternative

clofazimine + sotalol

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sufentanil
Lamprene (clofazimine)

+

sufentanil

1 interaction

Avoid/Use Alternative

clofazimine + sufentanil

consider alternative or monitor resp. rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• tazemetostat
Lamprene (clofazimine)

+

tazemetostat

1 interaction

Avoid/Use Alternative

clofazimine + tazemetostat

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• tetrabenazine
Lamprene (clofazimine)

+

tetrabenazine

1 interaction

Avoid/Use Alternative

clofazimine + tetrabenazine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tolvaptan
Lamprene (clofazimine)

+

tolvaptan

1 interaction

Avoid/Use Alternative

clofazimine + tolvaptan

HYPONATREMIA USE: avoid combo; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DZ USE: decr. tolvaptan total daily dose by 50% as follows: if taking 60 mg/day, decr. to 15 mg qam and 15 mg qpm; if taking 90 mg/day, decr. to 30 mg qam and 15 mg qpm; if taking 120 mg/day, decr. to 45 mg qam and 15 mg qpm: combo may incr. tolvaptan levels, risk of adverse effects (hepatic metab. inhibited)

• toremifene
Lamprene (clofazimine)

+

toremifene

1 interaction

Avoid/Use Alternative

clofazimine + toremifene

use alternative or monitor ECG: combo may incr. toremifene levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• tramadol
Lamprene (clofazimine)

+

tramadol

1 interaction

Avoid/Use Alternative

clofazimine + tramadol

use alternative or monitor resp. rate, ECG, withdrawal sx; consider decr. tramadol dose: combo may incr. tramadol, alter active metabolite levels, incr. risk of CNS and resp. depression, psychomotor impairment, seizures, serotonin syndrome, QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metab. inhibited, may alter production of active metabolite; additive effects)

• trazodone
Lamprene (clofazimine)

+

trazodone

1 interaction

Avoid/Use Alternative

clofazimine + trazodone

use alternative or monitor ECG, BP: combo may incr. trazodone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (incl. orthostasis, syncope), other adverse effects (hepatic metab. inhibited, additive effects)

• triptorelin
Lamprene (clofazimine)

+

triptorelin

1 interaction

Avoid/Use Alternative

clofazimine + triptorelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• typhoid vaccine, live
Lamprene (clofazimine)

+

typhoid vaccine, live

1 interaction

Avoid/Use Alternative

clofazimine + typhoid vaccine, live

avoid vaccine course during and w/in 72h of clofazimine use; if possible, delay clofazimine until at least 72h after last vaccine dose: combo may result in inadequate vaccine response (antibiotic effect may inactivate vaccine)

• vandetanib
Lamprene (clofazimine)

+

vandetanib

1 interaction

Avoid/Use Alternative

clofazimine + vandetanib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vardenafil
Lamprene (clofazimine)

+

vardenafil

1 interaction

Avoid/Use Alternative

clofazimine + vardenafil

monitor ECG; max vardenafil dose 5 mg/24h; avoid combo w/ ODT form: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metab. inhibited, additive effects)

• vemurafenib
Lamprene (clofazimine)

+

vemurafenib

1 interaction

Avoid/Use Alternative

clofazimine + vemurafenib

use alternative or monitor ECG, electrolytes: combo may incr. vemurafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• venetoclax
Lamprene (clofazimine)

+

venetoclax

1 interaction

Avoid/Use Alternative

clofazimine + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metab. inhibited)

• ziprasidone
Lamprene (clofazimine)

+

ziprasidone

1 interaction

Avoid/Use Alternative

clofazimine + ziprasidone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Monitor/Modify Tx

• abemaciclib
Lamprene (clofazimine)

+

abemaciclib

1 interaction

Monitor/Modify Tx

clofazimine + abemaciclib

consider decr. abemaciclib 200 mg bid dose to 150 mg bid, abemaciclib 150 mg bid dose to 100 mg bid, abemaciclib 100 mg bid dose to 50 mg bid; monitor CBC: combo may incr. abemaciclib levels, risk of serious infection, myelosuppression, thrombosis risk, other adverse effects (hepatic metab. inhibited)

• acalabrutinib
Lamprene (clofazimine)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

clofazimine + acalabrutinib

decr. acalabrutinib dose to 100 mg qd; monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• albuterol
Lamprene (clofazimine)

+

albuterol

1 interaction

Monitor/Modify Tx

clofazimine + albuterol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• albuterol inhaled
Lamprene (clofazimine)

+

albuterol inhaled

1 interaction

Monitor/Modify Tx

clofazimine + albuterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• alfuzosin
Lamprene (clofazimine)

+

alfuzosin

1 interaction

Monitor/Modify Tx

clofazimine + alfuzosin

monitor BP, ECG: combo may incr. alfuzosin levels, risk of QT prolongation, cardiac arrhythmias, hypotension (incl. orthostasis, syncope), other adverse effects (hepatic metab. inhibited, additive effects)

• amisulpride
Lamprene (clofazimine)

+

amisulpride

1 interaction

Monitor/Modify Tx

clofazimine + amisulpride

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amitriptyline
Lamprene (clofazimine)

+

amitriptyline

1 interaction

Monitor/Modify Tx

clofazimine + amitriptyline

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apalutamide
Lamprene (clofazimine)

+

apalutamide

1 interaction

Monitor/Modify Tx

clofazimine + apalutamide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apixaban
Lamprene (clofazimine)

+

apixaban

1 interaction

Monitor/Modify Tx

clofazimine + apixaban

monitor bleeding s/sx, especially if also combined w/ P-gp inhibitor: combo may incr. apixaban levels, risk of bleeding, other adverse effects (hepatic metab. inhibited)

• arformoterol inhaled
Lamprene (clofazimine)

+

arformoterol inhaled

1 interaction

Monitor/Modify Tx

clofazimine + arformoterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aripiprazole oral
Lamprene (clofazimine)

+

aripiprazole oral

1 interaction

Monitor/Modify Tx

clofazimine + aripiprazole oral

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metab. inhibited)

• asciminib
Lamprene (clofazimine)

+

asciminib

1 interaction

Monitor/Modify Tx

clofazimine + asciminib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• atorvastatin
Lamprene (clofazimine)

+

atorvastatin

1 interaction

Monitor/Modify Tx

clofazimine + atorvastatin

monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• avanafil
Lamprene (clofazimine)

+

avanafil

1 interaction

Monitor/Modify Tx

clofazimine + avanafil

monitor BP; adjust max avanafil dose to 50 mg/24h: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• avatrombopag
Lamprene (clofazimine)

+

avatrombopag

1 interaction

Monitor/Modify Tx

clofazimine + avatrombopag

CHRONIC IMMUNE THROMBOCYTOPENIA: if also combined w/ a mod-strong CYP2C9 inhibitor, decr. start dose to 20 mg 3x/wk and monitor platelets, thrombosis s/sx; otherwise, monitor platelets, thrombosis s/sx; CHRONIC LIVER DZ: monitor platelets, thrombosis s/sx: combo may incr. avatrombopag levels, risk of thromboembolism, other adverse effects (hepatic metab. inhibited)

• axitinib
Lamprene (clofazimine)

+

axitinib

1 interaction

Monitor/Modify Tx

clofazimine + axitinib

consider decr. axitinib dose: combo may incr. axitinib levels, risk of adverse effects (hepatic metab. inhibited)

• berotralstat
Lamprene (clofazimine)

+

berotralstat

1 interaction

Monitor/Modify Tx

clofazimine + berotralstat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• brexpiprazole
Lamprene (clofazimine)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

clofazimine + brexpiprazole

if CYP2D6 poor metabolizer or if also combined w/ moderate or strong CYP2D6 inhibitor, decr. brexpiprazole dose 75%: combo may incr. brexpiprazole levels, risk of adverse effects (hepatic metab. inhibited)

• bromocriptine
Lamprene (clofazimine)

+

bromocriptine

1 interaction

Monitor/Modify Tx

clofazimine + bromocriptine

limit bromocriptine max dose to 1.6 mg/day if diabetes tx; otherwise, caution advised: combo may incr. bromocriptine levels, risk of adverse effects (hepatic metab. inhibited)

• budesonide
Lamprene (clofazimine)

+

budesonide

1 interaction

Monitor/Modify Tx

clofazimine + budesonide

monitor hypercorticism s/sx: combo may incr. budesonide levels, risk of systemic corticosteroid effects, incl. Cushing syndrome, adrenal suppression, serious infection, other adverse effects (hepatic metab. inhibited)

• buprenorphine
Lamprene (clofazimine)

+

buprenorphine

1 interaction

Monitor/Modify Tx

clofazimine + buprenorphine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• butorphanol
Lamprene (clofazimine)

+

butorphanol

1 interaction

Monitor/Modify Tx

clofazimine + butorphanol

monitor resp. rate, consider decr. butorphanol dose: combo may incr. butorphanol levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• capivasertib
Lamprene (clofazimine)

+

capivasertib

1 interaction

Monitor/Modify Tx

clofazimine + capivasertib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• carbamazepine
Lamprene (clofazimine)

+

carbamazepine

1 interaction

Monitor/Modify Tx

clofazimine + carbamazepine

monitor carbamazepine levels: combo may incr. carbamazepine levels, risk of adverse effects (hepatic metab. inhibited)

• cariprazine
Lamprene (clofazimine)

+

cariprazine

1 interaction

Monitor/Modify Tx

clofazimine + cariprazine

if starting cariprazine tx, adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 1.5 mg qod, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 1.5 mg qod; if on stable cariprazine tx and starting clofazimine, adjust cariprazine dose as follows: ALL INDICATIONS: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 1.5 mg qod; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metab. inhibited)

• ceritinib
Lamprene (clofazimine)

+

ceritinib

1 interaction

Monitor/Modify Tx

clofazimine + ceritinib

monitor ECG, electrolytes: combo may incr. ceritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• chloroquine
Lamprene (clofazimine)

+

chloroquine

1 interaction

Monitor/Modify Tx

clofazimine + chloroquine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chlorpromazine
Lamprene (clofazimine)

+

chlorpromazine

1 interaction

Monitor/Modify Tx

clofazimine + chlorpromazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• cilostazol
Lamprene (clofazimine)

+

cilostazol

1 interaction

Monitor/Modify Tx

clofazimine + cilostazol

decr. cilostazol dose to 50 mg bid: combo may incr. cilostazol levels, risk of adverse effects (hepatic metab. inhibited)

• ciprofloxacin
Lamprene (clofazimine)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

clofazimine + ciprofloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clomipramine
Lamprene (clofazimine)

+

clomipramine

1 interaction

Monitor/Modify Tx

clofazimine + clomipramine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clonazepam
Lamprene (clofazimine)

+

clonazepam

1 interaction

Monitor/Modify Tx

clofazimine + clonazepam

monitor resp. rate: combo may incr. clonazepam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• clozapine
Lamprene (clofazimine)

+

clozapine

1 interaction

Monitor/Modify Tx

clofazimine + clozapine

monitor ECG, BP, HR, electrolytes; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, other adverse effects (hepatic metab. inhibited, additive effects)

• copanlisib
Lamprene (clofazimine)

+

copanlisib

1 interaction

Monitor/Modify Tx

clofazimine + copanlisib

monitor CBC: combo may incr. copanlisib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• cyclosporine
Lamprene (clofazimine)

+

cyclosporine

1 interaction

Monitor/Modify Tx

clofazimine + cyclosporine

monitor cyclosporine levels, renal fxn: combo may incr. cyclosporine levels, risk of serious infection, nephrotoxicity, other adverse effects (hepatic metab. inhibited)

• daridorexant
Lamprene (clofazimine)

+

daridorexant

1 interaction

Monitor/Modify Tx

clofazimine + daridorexant

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• dasatinib
Lamprene (clofazimine)

+

dasatinib

1 interaction

Monitor/Modify Tx

clofazimine + dasatinib

monitor ECG, electrolytes, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• deflazacort
Lamprene (clofazimine)

+

deflazacort

1 interaction

Monitor/Modify Tx

clofazimine + deflazacort

decr. deflazacort to 1/3 usual dose: combo may incr. deflazacort active metabolite levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression (hepatic metab. inhibited)

• deutetrabenazine
Lamprene (clofazimine)

+

deutetrabenazine

1 interaction

Monitor/Modify Tx

clofazimine + deutetrabenazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• docetaxel
Lamprene (clofazimine)

+

docetaxel

1 interaction

Monitor/Modify Tx

clofazimine + docetaxel

monitor CBC; consider decr. docetaxel dose: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• donepezil
Lamprene (clofazimine)

+

donepezil

1 interaction

Monitor/Modify Tx

clofazimine + donepezil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• elexacaftor/tezacaftor/ivacaftor
Lamprene (clofazimine)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

clofazimine + elexacaftor/ tezacaftor/ ivacaftor

2-5 YO: decr. dose by alternating one elexacaftor/tezacaftor/ivacaftor packet or one ivacaftor packet at each morning dose, no evening doses; 6 YO AND OLDER: decr. dose by alternating two elexacaftor/tezacaftor/ivacaftor tabs or one ivacaftor tab at each morning dose, no evening doses: combo may incr. elexacaftor/tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metab. inhibited)

• epirubicin
Lamprene (clofazimine)

+

epirubicin

1 interaction

Monitor/Modify Tx

clofazimine + epirubicin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eplerenone
Lamprene (clofazimine)

+

eplerenone

1 interaction

Monitor/Modify Tx

clofazimine + eplerenone

monitor potassium, Cr in 3-7 days after tx start; in post-MI CHF pts, max eplerenone dose 25 mg/day; in HTN pts, start eplerenone 25 mg qd, max dose 50 mg/day: combo may incr. eplerenone levels, risk of hyperkalemia, serious arrhythmias, other adverse effects (hepatic metab. inhibited)

• erdafitinib
Lamprene (clofazimine)

+

erdafitinib

1 interaction

Monitor/Modify Tx

clofazimine + erdafitinib

monitor phosphate: combo may incr. erdafitinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• escitalopram
Lamprene (clofazimine)

+

escitalopram

1 interaction

Monitor/Modify Tx

clofazimine + escitalopram

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• estazolam
Lamprene (clofazimine)

+

estazolam

1 interaction

Monitor/Modify Tx

clofazimine + estazolam

monitor resp. rate; consider decr. estazolam dose: combo may incr. estazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• estradiol (contraceptive)
Lamprene (clofazimine)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

clofazimine + estradiol (contraceptive)

monitor thrombosis s/sx: combo may incr. estradiol levels, risk of thromboembolism, other adverse effects (hepatic metab. inhibited)

• ethinyl estradiol (contraceptive)
Lamprene (clofazimine)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

clofazimine + ethinyl estradiol (contraceptive)

monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metab. inhibited)

• everolimus
Lamprene (clofazimine)

+

everolimus

1 interaction

Monitor/Modify Tx

clofazimine + everolimus

BREAST CA, PNET, RENAL CELL CA, or RENAL ANGIOMYOLIPOMA w/ TSC: if also combined w/ P-gp inhibitor, decr. everolimus to 2.5 mg/day, may incr. to 5 mg/day if tolerated, monitor CBC; otherwise, monitor CBC; TSC-ASSOC. SEGA or TSC-ASSOC. PARTIAL-ONSET SEIZURES: if also combined w/ P-gp inhibitor, monitor everolimus levels, CBC and decr. everolimus 50%; give every other day if already on lowest available dose; otherwise, monitor everolimus levels, CBC; TRANSPLANT: monitor everolimus levels, CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• fedratinib
Lamprene (clofazimine)

+

fedratinib

1 interaction

Monitor/Modify Tx

clofazimine + fedratinib

if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs: combo may incr. fedratinib levels, risk of myelosuppression, hepatotoxicity, other adverse effects (hepatic metab. inhibited)

• felodipine
Lamprene (clofazimine)

+

felodipine

1 interaction

Monitor/Modify Tx

clofazimine + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metab. inhibited)

• finerenone
Lamprene (clofazimine)

+

finerenone

1 interaction

Monitor/Modify Tx

clofazimine + finerenone

monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metab. inhibited)

• fingolimod
Lamprene (clofazimine)

+

fingolimod

1 interaction

Monitor/Modify Tx

clofazimine + fingolimod

monitor ECG overnight during fingolimod initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluconazole
Lamprene (clofazimine)

+

fluconazole

1 interaction

Monitor/Modify Tx

clofazimine + fluconazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluorouracil
Lamprene (clofazimine)

+

fluorouracil

1 interaction

Monitor/Modify Tx

clofazimine + fluorouracil

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• formoterol inhaled
Lamprene (clofazimine)

+

formoterol inhaled

1 interaction

Monitor/Modify Tx

clofazimine + formoterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fostemsavir
Lamprene (clofazimine)

+

fostemsavir

1 interaction

Monitor/Modify Tx

clofazimine + fostemsavir

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• futibatinib
Lamprene (clofazimine)

+

futibatinib

1 interaction

Monitor/Modify Tx

clofazimine + futibatinib

monitor phosphate: combo may incr. futibatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• gemtuzumab ozogamicin
Lamprene (clofazimine)

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

clofazimine + gemtuzumab ozogamicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gepirone
Lamprene (clofazimine)

+

gepirone

1 interaction

Monitor/Modify Tx

clofazimine + gepirone

monitor ECG, electrolytes; decr. gepirone dose 50%: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• gilteritinib
Lamprene (clofazimine)

+

gilteritinib

1 interaction

Monitor/Modify Tx

clofazimine + gilteritinib

monitor ECG, electrolytes: combo may incr. gilteritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• granisetron
Lamprene (clofazimine)

+

granisetron

1 interaction

Monitor/Modify Tx

clofazimine + granisetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• guanfacine
Lamprene (clofazimine)

+

guanfacine

1 interaction

Monitor/Modify Tx

clofazimine + guanfacine

decr. guanfacine ER dose 50%, consider decr. dose for immed.-release form: combo may incr. guanfacine levels, risk of adverse effects (hepatic metab. inhibited)

• haloperidol
Lamprene (clofazimine)

+

haloperidol

1 interaction

Monitor/Modify Tx

clofazimine + haloperidol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• hydrocortisone
Lamprene (clofazimine)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

clofazimine + hydrocortisone

consider decr. hydrocortisone dose: combo may incr. hydrocortisone levels, risk of systemic corticosteroid effects, incl. Cushing syndrome and adrenal suppression, other adverse effects (hepatic metab. inhibited)

• hydroxyzine
Lamprene (clofazimine)

+

hydroxyzine

1 interaction

Monitor/Modify Tx

clofazimine + hydroxyzine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibrutinib
Lamprene (clofazimine)

+

ibrutinib

1 interaction

Monitor/Modify Tx

clofazimine + ibrutinib

B-CELL MALIGNANCIES: decr. ibrutinib dose to 280 mg qd; CHRONIC GVHD: consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• irinotecan
Lamprene (clofazimine)

+

irinotecan

1 interaction

Monitor/Modify Tx

clofazimine + irinotecan

monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (hepatic metab. inhibited)

• itraconazole
Lamprene (clofazimine)

+

itraconazole

1 interaction

Monitor/Modify Tx

clofazimine + itraconazole

consider decr. itraconazole dose: combo may incr. itraconazole levels, risk of adverse effects (hepatic metab. inhibited)

• lapatinib
Lamprene (clofazimine)

+

lapatinib

1 interaction

Monitor/Modify Tx

clofazimine + lapatinib

monitor ECG; consider decr. lapatinib dose: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lenvatinib
Lamprene (clofazimine)

+

lenvatinib

1 interaction

Monitor/Modify Tx

clofazimine + lenvatinib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levalbuterol inhaled
Lamprene (clofazimine)

+

levalbuterol inhaled

1 interaction

Monitor/Modify Tx

clofazimine + levalbuterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lidocaine
Lamprene (clofazimine)

+

lidocaine

1 interaction

Monitor/Modify Tx

clofazimine + lidocaine

monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher w/ continuous infusion or higher doses for local anesthesia (hepatic metab. inhibited)

• lofexidine
Lamprene (clofazimine)

+

lofexidine

1 interaction

Monitor/Modify Tx

clofazimine + lofexidine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lumateperone
Lamprene (clofazimine)

+

lumateperone

1 interaction

Monitor/Modify Tx

clofazimine + lumateperone

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lurasidone
Lamprene (clofazimine)

+

lurasidone

1 interaction

Monitor/Modify Tx

clofazimine + lurasidone

monitor ECG; decr. lurasidone start dose to 20 mg or decr. usual lurasidone dose 50%, max 80 mg/day: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• mavacamten
Lamprene (clofazimine)

+

mavacamten

1 interaction

Monitor/Modify Tx

clofazimine + mavacamten

monitor cardiac fxn, incl. LVEF; if pt stable on clofazimine tx, initiate mavacamten at 5 mg qd; if adding short-term (<1wk) clofazimine tx to existing mavacamten tx, hold mavacamten until clofazimine D/C; if adding longer-term (>1wk) clofazimine tx, decr. mavacamten dose as follows for at least 12wk: decr. mavacamten 15 mg qd to 10 mg qd; decr. mavacamten 10 mg qd to 5 mg qd; decr. mavacamten 5 mg qd to 2.5 mg qd; do not start clofazimine tx if on mavacamten 2.5 mg qd: combo may incr. mavacamten levels, risk of heart failure, other adverse effects (hepatic metab. inhibited)

• mavorixafor
Lamprene (clofazimine)

+

mavorixafor

1 interaction

Monitor/Modify Tx

clofazimine + mavorixafor

monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• mefloquine
Lamprene (clofazimine)

+

mefloquine

1 interaction

Monitor/Modify Tx

clofazimine + mefloquine

monitor ECG: combo may incr. mefloquine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• metronidazole
Lamprene (clofazimine)

+

metronidazole

1 interaction

Monitor/Modify Tx

clofazimine + metronidazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• midostaurin
Lamprene (clofazimine)

+

midostaurin

1 interaction

Monitor/Modify Tx

clofazimine + midostaurin

monitor ECG, CBC: combo may incr. midostaurin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• mirtazapine
Lamprene (clofazimine)

+

mirtazapine

1 interaction

Monitor/Modify Tx

clofazimine + mirtazapine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mitapivat
Lamprene (clofazimine)

+

mitapivat

1 interaction

Monitor/Modify Tx

clofazimine + mitapivat

monitor Hgb; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects (hepatic metab. inhibited)

• nifedipine
Lamprene (clofazimine)

+

nifedipine

1 interaction

Monitor/Modify Tx

clofazimine + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nimodipine
Lamprene (clofazimine)

+

nimodipine

1 interaction

Monitor/Modify Tx

clofazimine + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nortriptyline
Lamprene (clofazimine)

+

nortriptyline

1 interaction

Monitor/Modify Tx

clofazimine + nortriptyline

monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metab. inhibited)

• ofloxacin
Lamprene (clofazimine)

+

ofloxacin

1 interaction

Monitor/Modify Tx

clofazimine + ofloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olodaterol inhaled
Lamprene (clofazimine)

+

olodaterol inhaled

1 interaction

Monitor/Modify Tx

clofazimine + olodaterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ondansetron
Lamprene (clofazimine)

+

ondansetron

1 interaction

Monitor/Modify Tx

clofazimine + ondansetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• osilodrostat
Lamprene (clofazimine)

+

osilodrostat

1 interaction

Monitor/Modify Tx

clofazimine + osilodrostat

monitor ECG: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited; additive effects)

• paclitaxel
Lamprene (clofazimine)

+

paclitaxel

1 interaction

Monitor/Modify Tx

clofazimine + paclitaxel

monitor CBC: combo may incr. paclitaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. possibly inhibited)

• palbociclib
Lamprene (clofazimine)

+

palbociclib

1 interaction

Monitor/Modify Tx

clofazimine + palbociclib

monitor CBC: combo may incr. palbociclib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• palonosetron
Lamprene (clofazimine)

+

palonosetron

1 interaction

Monitor/Modify Tx

clofazimine + palonosetron

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pasireotide
Lamprene (clofazimine)

+

pasireotide

1 interaction

Monitor/Modify Tx

clofazimine + pasireotide

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pirtobrutinib
Lamprene (clofazimine)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

clofazimine + pirtobrutinib

monitor CBC: combo may incr. pirtobrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ponatinib
Lamprene (clofazimine)

+

ponatinib

1 interaction

Monitor/Modify Tx

clofazimine + ponatinib

monitor CBC: combo may incr. ponatinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• posaconazole
Lamprene (clofazimine)

+

posaconazole

1 interaction

Monitor/Modify Tx

clofazimine + posaconazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• primaquine
Lamprene (clofazimine)

+

primaquine

1 interaction

Monitor/Modify Tx

clofazimine + primaquine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• promethazine
Lamprene (clofazimine)

+

promethazine

1 interaction

Monitor/Modify Tx

clofazimine + promethazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propranolol
Lamprene (clofazimine)

+

propranolol

1 interaction

Monitor/Modify Tx

clofazimine + propranolol

monitor BP, HR: combo may incr. propranolol levels, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metab. possibly inhibited)

• quinidine (CYP2D6 inhibitor)
Lamprene (clofazimine)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Monitor/Modify Tx

clofazimine + quinidine (CYP2D6 inhibitor)

monitor ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ranolazine
Lamprene (clofazimine)

+

ranolazine

1 interaction

Monitor/Modify Tx

clofazimine + ranolazine

monitor ECG; adjust ranolazine max dose to 1000 mg/day: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• red yeast rice
Lamprene (clofazimine)

+

red yeast rice

1 interaction

Monitor/Modify Tx

clofazimine + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, red yeast rice contains varying amounts of lovastatin)

• relugolix
Lamprene (clofazimine)

+

relugolix

1 interaction

Monitor/Modify Tx

clofazimine + relugolix

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• repaglinide
Lamprene (clofazimine)

+

repaglinide

1 interaction

Monitor/Modify Tx

clofazimine + repaglinide

monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic metab. inhibited)

• rifabutin
Lamprene (clofazimine)

+

rifabutin

1 interaction

Monitor/Modify Tx

clofazimine + rifabutin

monitor CBC, uveitis s/sx: combo may incr. rifabutin levels, risk of myelosuppression, uveitis, other adverse effects (hepatic metab. inhibited)

• rimegepant
Lamprene (clofazimine)

+

rimegepant

1 interaction

Monitor/Modify Tx

clofazimine + rimegepant

separate rimegepant doses by at least 48h: combo may incr. rimegepant levels, risk of adverse effects (hepatic metab. inhibited)

• riociguat
Lamprene (clofazimine)

+

riociguat

1 interaction

Monitor/Modify Tx

clofazimine + riociguat

monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (hepatic metab. inhibited)

• romidepsin
Lamprene (clofazimine)

+

romidepsin

1 interaction

Monitor/Modify Tx

clofazimine + romidepsin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ruxolitinib
Lamprene (clofazimine)

+

ruxolitinib

1 interaction

Monitor/Modify Tx

clofazimine + ruxolitinib

monitor CBC: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ruxolitinib topical
Lamprene (clofazimine)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

clofazimine + ruxolitinib topical

monitor CBC: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• sacituzumab govitecan
Lamprene (clofazimine)

+

sacituzumab govitecan

1 interaction

Monitor/Modify Tx

clofazimine + sacituzumab govitecan

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• salmeterol inhaled
Lamprene (clofazimine)

+

salmeterol inhaled

1 interaction

Monitor/Modify Tx

clofazimine + salmeterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sirolimus
Lamprene (clofazimine)

+

sirolimus

1 interaction

Monitor/Modify Tx

clofazimine + sirolimus

monitor sirolimus levels: combo may incr. sirolimus levels, risk of serious infection, other adverse effects (hepatic metab. inhibited)

• sirolimus albumin-bound
Lamprene (clofazimine)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

clofazimine + sirolimus albumin-bound

decr. sirolimus albumin-bound dose to 56 mg/m2; monitor CBC, bleeding s/sx: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• sparsentan
Lamprene (clofazimine)

+

sparsentan

1 interaction

Monitor/Modify Tx

clofazimine + sparsentan

monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (incl. orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metab. inhibited)

• sunitinib
Lamprene (clofazimine)

+

sunitinib

1 interaction

Monitor/Modify Tx

clofazimine + sunitinib

monitor ECG, electrolytes: combo may incr. sunitinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• suvorexant
Lamprene (clofazimine)

+

suvorexant

1 interaction

Monitor/Modify Tx

clofazimine + suvorexant

decr. suvorexant dose to 5 mg, max 10 mg/day: combo may incr. suvorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• suzetrigine
Lamprene (clofazimine)

+

suzetrigine

1 interaction

Monitor/Modify Tx

clofazimine + suzetrigine

start suzetrigine 100 mg x1 at least 1h before or 2h after food, after 12h give 50 mg q12h x3 doses, then after 12h give 50mg q24h: combo may incr. suzetrigine and active metabolite levels, risk of adverse effects (hepatic metab. inhibited)

• tacrolimus
Lamprene (clofazimine)

+

tacrolimus

1 interaction

Monitor/Modify Tx

clofazimine + tacrolimus

monitor tacrolimus levels, ECG, electrolytes, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects (hepatic metab. inhibited, additive effects)

• tadalafil
Lamprene (clofazimine)

+

tadalafil

1 interaction

Monitor/Modify Tx

clofazimine + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• tamsulosin
Lamprene (clofazimine)

+

tamsulosin

1 interaction

Monitor/Modify Tx

clofazimine + tamsulosin

monitor BP, especially w/ tamsulosin dose >0.4 mg: combo may incr. tamsulosin levels, risk of hypotension (incl. orthostasis, syncope), other adverse effects (hepatic metab. inhibited)

• telavancin
Lamprene (clofazimine)

+

telavancin

1 interaction

Monitor/Modify Tx

clofazimine + telavancin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• temsirolimus
Lamprene (clofazimine)

+

temsirolimus

1 interaction

Monitor/Modify Tx

clofazimine + temsirolimus

monitor CBC; consider decr. temsirolimus dose: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• terbutaline
Lamprene (clofazimine)

+

terbutaline

1 interaction

Monitor/Modify Tx

clofazimine + terbutaline

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tezacaftor/ivacaftor
Lamprene (clofazimine)

+

tezacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

clofazimine + tezacaftor/ ivacaftor

decr. dose by alternating tezacaftor/ivacaftor tab and ivacaftor tab at morning dose, no evening doses: combo may incr. tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metab. inhibited)

• tofacitinib
Lamprene (clofazimine)

+

tofacitinib

1 interaction

Monitor/Modify Tx

clofazimine + tofacitinib

monitor CBC; if also combined w/ strong CYP2C19 inhibitor, adjust tofacitinib dose as follows: RHEUMATOID or PSORIATIC ARTHRITIS: decr. tofacitinib dose to 5 mg qd; ULCERATIVE COLITIS: decr. tofacitinib 22 mg qd dose to 11 mg qd; decr. tofacitinib 11 mg qd dose to 5 mg qd; decr. tofacitinib 10 mg bid dose to 5 mg bid; decr. tofacitinib 5 mg bid dose to 5 mg qd; JUVENILE IDIOPATHIC ARTHRITIS: decr. usual tofacitinib bid dose to qd: combo may incr. tofacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• tolterodine
Lamprene (clofazimine)

+

tolterodine

1 interaction

Monitor/Modify Tx

clofazimine + tolterodine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trabectedin
Lamprene (clofazimine)

+

trabectedin

1 interaction

Monitor/Modify Tx

clofazimine + trabectedin

monitor CBC, cardiac fxn, LFTs: combo may incr. trabectedin levels, risk of myelosuppression, cardiotoxicity, hepatotoxicity, other adverse effects (hepatic metab. inhibited)

• triazolam
Lamprene (clofazimine)

+

triazolam

1 interaction

Monitor/Modify Tx

clofazimine + triazolam

monitor resp. rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• triclabendazole
Lamprene (clofazimine)

+

triclabendazole

1 interaction

Monitor/Modify Tx

clofazimine + triclabendazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluridine
Lamprene (clofazimine)

+

trifluridine

1 interaction

Monitor/Modify Tx

clofazimine + trifluridine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ubrogepant
Lamprene (clofazimine)

+

ubrogepant

1 interaction

Monitor/Modify Tx

clofazimine + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 24h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metab. inhibited)

• valbenazine
Lamprene (clofazimine)

+

valbenazine

1 interaction

Monitor/Modify Tx

clofazimine + valbenazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vanzacaftor/tezacaftor/deutivacaftor
Lamprene (clofazimine)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Monitor/Modify Tx

clofazimine + vanzacaftor/ tezacaftor/ deutivacaftor

6-11 YO AND WT <40 KG: decr. vanzacaftor/tezacaftor/deutivacaftor dose to two tablets (4 mg/20 mg/50 mg each) qod; 6-11 YO AND WT 40 KG AND ABOVE: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qod; 12 YO AND OLDER: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qod: combo may incr. vanzacaftor/tezacaftor/deutivacaftor levels, risk of adverse effects (hepatic metab. inhibited)

• venlafaxine
Lamprene (clofazimine)

+

venlafaxine

1 interaction

Monitor/Modify Tx

clofazimine + venlafaxine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vilanterol inhaled
Lamprene (clofazimine)

+

vilanterol inhaled

1 interaction

Monitor/Modify Tx

clofazimine + vilanterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vinblastine
Lamprene (clofazimine)

+

vinblastine

1 interaction

Monitor/Modify Tx

clofazimine + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vincristine
Lamprene (clofazimine)

+

vincristine

1 interaction

Monitor/Modify Tx

clofazimine + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vinorelbine
Lamprene (clofazimine)

+

vinorelbine

1 interaction

Monitor/Modify Tx

clofazimine + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• voclosporin
Lamprene (clofazimine)

+

voclosporin

1 interaction

Monitor/Modify Tx

clofazimine + voclosporin

monitor ECG, electrolytes, renal fxn; decr. voclosporin morning dose to 15.8 mg and evening dose to 7.9 mg: combo may incr. voclosporin levels, risk of QT prolongation, cardiac arrhythmias, serious infection, nephrotoxicity, other adverse effects (hepatic metab. inhibited, additive effects)

• voriconazole
Lamprene (clofazimine)

+

voriconazole

1 interaction

Monitor/Modify Tx

clofazimine + voriconazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• warfarin
Lamprene (clofazimine)

+

warfarin

1 interaction

Monitor/Modify Tx

clofazimine + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited)

• zanubrutinib
Lamprene (clofazimine)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

clofazimine + zanubrutinib

decr. zanubrutinib dose to 80 mg bid; monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)